Teladoc Health [TDOC] vs 10x Genomics [TXG] Detailed Stock Comparison
Teladoc Health
NYSE
Loading...
10x Genomics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Teladoc Health wins in 11 metrics, 10x Genomics wins in 7 metrics, with 0 ties. Teladoc Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Teladoc Health | 10x Genomics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.31 | -9.41 | 10x Genomics |
| Price-to-Book Ratio | 0.95 | 2.30 | Teladoc Health |
| Debt-to-Equity Ratio | 72.78 | 11.22 | 10x Genomics |
| PEG Ratio | 0.01 | 0.05 | Teladoc Health |
| EV/EBITDA | 86.11 | -11.46 | 10x Genomics |
| Profit Margin (TTM) | -8.16% | -13.13% | Teladoc Health |
| Operating Margin (TTM) | -7.29% | -2.63% | 10x Genomics |
| Return on Equity | -14.18% | -11.30% | 10x Genomics |
| Return on Assets (TTM) | -3.57% | -9.45% | Teladoc Health |
| Free Cash Flow (TTM) | $169.63M | $-6.73M | Teladoc Health |
| 1-Year Return | 3.50% | -39.12% | Teladoc Health |
| Price-to-Sales Ratio (TTM) | 0.53 | 2.76 | Teladoc Health |
| Enterprise Value | $1.63B | $1.27B | Teladoc Health |
| EV/Revenue Ratio | 0.64 | 1.97 | Teladoc Health |
| Gross Profit Margin (TTM) | 69.85% | 72.34% | 10x Genomics |
| Revenue per Share (TTM) | $15 | $5 | Teladoc Health |
| Earnings per Share (Diluted) | $-1.15 | $-0.70 | 10x Genomics |
| Beta (Stock Volatility) | 1.77 | 2.03 | Teladoc Health |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Teladoc Health vs 10x Genomics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Teladoc Health | 6.82% | 2.13% | -8.79% | 11.30% | -32.57% | -19.33% |
| 10x Genomics | 9.16% | 7.04% | 10.08% | 67.45% | 26.66% | 0.78% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Teladoc Health | 3.50% | -76.07% | -96.32% | -72.29% | -72.57% | -72.57% |
| 10x Genomics | -39.12% | -59.01% | -87.04% | -72.64% | -72.64% | -72.64% |
Performance & Financial Health Analysis: Teladoc Health vs 10x Genomics
| Metric | TDOC | TXG |
|---|---|---|
| Market Information | ||
| Market Cap | $1.36B | $1.78B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 5,593,154 | 3,557,051 |
| 90 Day Avg. Volume | 7,100,158 | 3,267,257 |
| Last Close | $7.68 | $14.30 |
| 52 Week Range | $6.35 - $15.21 | $6.78 - $24.76 |
| % from 52W High | -49.51% | -42.25% |
| All-Time High | $308.00 (Feb 15, 2021) | $208.99 (Jun 28, 2021) |
| % from All-Time High | -97.51% | -93.16% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.13% |
| Quarterly Earnings Growth | -0.02% | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | -0.08% | -0.13% |
| Operating Margin (TTM) | -0.07% | -0.03% |
| Return on Equity (TTM) | -0.14% | -0.11% |
| Debt to Equity (MRQ) | 72.78 | 11.22 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $8.05 | $6.21 |
| Cash per Share (MRQ) | $3.85 | $3.59 |
| Operating Cash Flow (TTM) | $303.43M | $66.95M |
| Levered Free Cash Flow (TTM) | $209.72M | $58.22M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Teladoc Health vs 10x Genomics
| Metric | TDOC | TXG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.31 | -9.41 |
| Forward P/E | -8.63 | -11.72 |
| PEG Ratio | 0.01 | 0.05 |
| Price to Sales (TTM) | 0.53 | 2.76 |
| Price to Book (MRQ) | 0.95 | 2.30 |
| Market Capitalization | ||
| Market Capitalization | $1.36B | $1.78B |
| Enterprise Value | $1.63B | $1.27B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.64 | 1.97 |
| Enterprise to EBITDA | 86.11 | -11.46 |
| Risk & Other Metrics | ||
| Beta | 1.77 | 2.03 |
| Book Value per Share (MRQ) | $8.05 | $6.21 |
Financial Statements Comparison: Teladoc Health vs 10x Genomics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TDOC | TXG |
|---|---|---|
| Revenue/Sales | $629.37M | $154.88M |
| Cost of Goods Sold | $196.83M | $49.44M |
| Gross Profit | $432.54M | $105.45M |
| Research & Development | $69.96M | $64.25M |
| Operating Income (EBIT) | $-54.94M | $-48.53M |
| EBITDA | $50.34M | $-32.89M |
| Pre-Tax Income | $-111.27M | $-33.51M |
| Income Tax | $-18.26M | $852,000 |
| Net Income (Profit) | $-93.01M | $-34.36M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TDOC | TXG |
|---|---|---|
| Cash & Equivalents | $679.62M | $377.06M |
| Total Current Assets | $1.07B | $579.73M |
| Total Current Liabilities | $401.77M | $107.90M |
| Long-Term Debt | $1.03B | $70.63M |
| Total Shareholders Equity | $1.42B | $706.90M |
| Retained Earnings | $-16.36B | $-1.50B |
| Property, Plant & Equipment | $27.67M | $55.58M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TDOC | TXG |
|---|---|---|
| Operating Cash Flow | $89.56M | $35.44M |
| Capital Expenditures | N/A | $-1.89M |
| Free Cash Flow | $31.63M | $32.46M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TDOC | TXG |
|---|---|---|
| Shares Short | 24.01M | 14.46M |
| Short Ratio | 3.17 | 4.59 |
| Short % of Float | 0.15% | 0.19% |
| Average Daily Volume (10 Day) | 5,593,154 | 3,557,051 |
| Average Daily Volume (90 Day) | 7,100,158 | 3,267,257 |
| Shares Outstanding | 173.41M | 122.29M |
| Float Shares | 174.77M | 112.38M |
| % Held by Insiders | 0.01% | 0.02% |
| % Held by Institutions | 0.74% | 1.05% |
Dividend Analysis & Yield Comparison: Teladoc Health vs 10x Genomics
| Metric | TDOC | TXG |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |